Your best source on business and economy news from Michigan
Provided by AGP
SpyGlass Pharma to Participate in Upcoming Investor Conferences
ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences:
Stifel 2026 Virtual Ophthalmology Forum
Date: Tuesday, May 26, 2026
Time: 2:00 p.m. ET
Format: Fireside Chat
Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 2:35 p.m. ET
Format: Fireside Chat
Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Time: 10:40 a.m. ET
Format: Corporate Presentation
A live webcast and subsequent replay of each presentation can be accessed via the Investor Relations section of the Company website at www.spyglasspharma.com.
About SpyGlass Pharma
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.
The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine.
Media Contact:
Nami Surendranath
+1 (402) 507-6757
nsurendranath@dnacommunications.com
Investor Contact:
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
investors@spyglasspharma.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
